S
Shoreline's proprietary cell therapy technology platform is based on deep expertise in iPSC differentiation methods and genetic programming of the IL-15/CISH pathway for enhanced metabolic fitness and persistence of the engineered NK Cells to improve anti-cancer activity.
Investor insights
Funding rounds participated in
$140M sweet spot round size
Investor type
Privately Held
Basic info
Industry
Biotechnology Research
Sectors
Biotechnology Research
Date founded
2020
Funding rounds raised
Total raised
$140M
from 2 investors over 1 rounds
S
Shoreline Biosciences, Inc. raised $140M on December 2, 2021
Investors: Ally Bridge Group and + 13 Other investors